EC
VRNA

EntryPoint Capital’s Verona Pharma VRNA Stock Holding History

EntryPoint Capital’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,125
Closed -$406K – 982
2024
Q3 		$406K Buy
+14,125
New +$348K 0.23% 119
2024
Q2 		– Sell
-1,175
Closed -$18.9K – 1661
2024
Q1 		$18.9K Buy
+1,175
New +$20.3K 0.02% 1112

Other funds holding VRNA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EntryPoint Capital's VRNA Position: Q4 2024 in Review

EntryPoint Capital sold out of Verona Pharma (VRNA) in Q4 2024, closing a stake of 14,125 shares — an estimated $406K sold.

EntryPoint Capital first reported a position in VRNA in Q1 2024 and held it in 2 quarters. The position peaked at $406K in Q3 2024. 191 funds tracked by Wall St. Rank hold VRNA as of Q4 2024.

  • EntryPoint Capital reported no remaining Verona Pharma position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 14,125 Verona Pharma shares in Q4 2024, an estimated $406K.
  • EntryPoint Capital first reported a position in Verona Pharma in Q1 2024 and held it in 2 quarters.
  • EntryPoint Capital's Verona Pharma position peaked at $406K in Q3 2024.
  • 191 funds tracked by Wall St. Rank held Verona Pharma as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.